Neurostimulator devices have gained traction in 2017, evidenced by regulatory developments and compelling new data highlighting their utility in the management of epilepsy. In June, the FDA approved LivaNova’s Vagus Nerve Stimulation (VNS) Therapy Programming System, a minimally invasive treatment…